Table 2.
The relationship between the serum levels of S100A11 and MMP-9 and clinicopathological characteristics in patients with EOC.
| Clinical variable | No. of patients | S100A11 (ng/mL) Median (range) |
P valuea | MMP-9(ng/mL) Median (range) |
P valuea |
|---|---|---|---|---|---|
| All cases | 111 | ||||
| Age at diagnosis(years) | 0.201 | 0.136 | |||
| <51 | 55 | 11.01 (4.46-32.74) | 165.53 (35.21-688.99) | ||
| ≥51 | 56 | 15.60 (5.60-38.86) | 199.61 (59.01-475.02) | ||
| Histological type | 0.32 | 0.678 | |||
| Serous | 80 | 13.41 (4.46-32.22) | 180.51 (35.21-475.02) | ||
| Mucinous | 10 | 12.58 (7.60-32.75) | 195.80 (63.42-688.99) | ||
| Endometrioid | 13 | 10.75 (6.38-38.86) | 151.90 (47.22-422.59) | ||
| Clear cell tumor | 8 | 12.32 (8.13-29.86) | 153.26 (55.59-248.06) | ||
| Tumor grade | 0.93 | 0.978 | |||
| G1 | 8 | 13.02 (8.03-22.62) | 182.96 (63.42-441.95) | ||
| G2 | 23 | 11.71 (6.38-32.22) | 156.85 (47.22-422.59) | ||
| G3 | 80 | 13.02 (4.46-38.86) | 181.38 (35.21-688.99) | ||
| Lymph node metastasis | 0.01 | 0.007 | |||
| Negative | 60 | 12.58 (4.46-32.75) | 154.03 (35.21-688.99) | ||
| Positive | 51 | 14.24 (5.60-38.86) | 204.23 (63.47-475.02) | ||
| FIGO stage | <0.001 | <0.001 | |||
| I, II | 30 | 10.00 (6.38-29.86) | 139.94 (43.82-246.16) | ||
| III, IV | 81 | 14.15 (4.46-38.86) | 199.65 (35.21-688.99) | ||
| Serum CA125 level (U/mL) | 0.04 | 0.002 | |||
| <35 | 26 | 12.32 (4.46-31.26) | 154.44 (35.21-441.95) | ||
| ≥35 | 85 | 14.29 (6.20-38.86) | 199.59 (43.82-688.99) | ||
| Chemotherapy resistanceb | 0.01 | <0.001 | |||
| Present | 31 | 12.32 (4.46-31.26) | 154.44 (35.21-441.95) | ||
| Absent | 79 | 14.29 (6.20-38.86) | 199.59 (43.82-688.99) | ||
| Ascites (mL) | 0.01 | 0.045 | |||
| <500 | 51 | 12.32 (4.46-31.26) | 154.44 (35.21-441.95) | ||
| ≥500 | 60 | 14.29 (6.20-38.86) | 199.59 (43.82-688.99) | ||
| Two-tier system | 0.52 | 0.29 | |||
| I type | 45 | 12.76 (6.38-38.86) | 156.85 (47.22-441.95) | ||
| II type | 66 | 13.19 (4.46-32.75) | 183.62 (35.21-688.99) | ||
| Residual tumor size (cm) | 0.03 | 0.002 | |||
| <2 | 86 | 12.76 (4.46-38.86) | 167.70 (35.21-688.99) | ||
| ≥2 | 25 | 15.81 (5.60-31.17) | 244.50 (83.18-344.22) |
aThe Mann–Whitney U and Kruskal-Wallis nonparametric tests were used to compare different groups. bOne patient with stage I and Grade I did not undergo chemotherapy.